Predict your next investment

Corporation
HEALTHCARE | Medical Product Distribution
jnj.com

See what CB Insights has to offer

Investments

95

Portfolio Exits

46

Partners & Customers

10

Service Providers

1

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a multi-national manufacturer of pharmaceutical, diagnostic, therapeutic, surgical, and biotechnology products, as well as personal hygiene products.

Johnson & Johnson Headquarter Location

One Johnson & Johnson Plaza

New Brunswick, New Jersey, 08933,

United States

732-524-2455

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Johnson & Johnson

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Johnson & Johnson in 6 Expert Collections, including Beauty & Personal Care.

B

Beauty & Personal Care

58 items

Startups in the beauty & personal care space, including cosmetics brands, shaving startups, on-demand beauty services, salon management platforms, and more.

S

Synthetic Biology

382 items

F

Fortune 500 Investor list

590 items

This is a collection of investors named in the 2019 Fortune 500 list of companies. All CB Insights profiles for active investment arms of a Fortune 500 company are included.

C

Conference Exhibitors

6,062 items

Companies that will be exhibiting at CES 2018

R

Regenerative Medicine

1,767 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

3

3D Printing

411 items

Johnson & Johnson Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Johnson & Johnson Rank

Latest Johnson & Johnson News

Breaking: Incidence of Blood Clot in Brain After Johnson & Johnson COVID-19 Vaccination

Nov 1, 2021

By JAMA NetworkNovember 1, 2021 At 11:00 am ET today (November 1, 2021), the results will be released for research that studied Incidence of blood clot in brain after Johnson & Johnson/Janssen COVID-19 vaccination. What The Study Did: Resarchers compared post-Ad26.COV2.S (Johnson & Johnson/Janssen) vaccination cerebral venous sinus thrombosis (CVST, a blood clot in the brain) rates with prepandemic rates to estimate postvaccination CVST risk. The rate of this rare adverse effect must be considered in the context of the effectiveness of the vaccine in preventing COVID-19. Authors: Aneel A. Ashrani, M.D., M.S., of the Mayo Clinic in Rochester, Minnesota, is the corresponding author. The study found a “significantly higher” brain blood clot (cerebral venous sinus thrombosis / CVST) incidence rate in people after vaccination with the Johnson & Johnson COVID-19 vaccine. The highest risk was in women between the ages of 30 and 49, with most CVST events happening within 15 days of vaccination. Although this is a serious side effect, the authors caution that “the higher rate of this rare adverse effect must be considered in the context of the effectiveness of the vaccine in preventing COVID-19.” Reference: “Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COV2.S COVID-19 Vaccination” by Aneel A. Ashrani, MD, MS; Daniel J. Crusan, BS; Tanya Petterson, MS; Kent Bailey, PhD and John A. Heit, MD, 1 November 2021, JAMA Internal Medicine. DOI: 10.1001/jamainternmed.2021.6352

Johnson & Johnson Investments

95 Investments

Johnson & Johnson has made 95 investments. Their latest investment was in OrthoSpin as part of their Series B on March 3, 2020.

CBI Logo

Johnson & Johnson Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

3/31/2020

Series B

OrthoSpin

$5M

Yes

10

11/14/2019

Corporate Minority - IV

Founders Factory

Yes

1

7/18/2018

Corporate Minority

S-Biomedic

Yes

3

2/2/2017

Series A

Subscribe to see more

$99M

Subscribe to see more

10

12/17/2015

Corporate Minority

Subscribe to see more

$99M

Subscribe to see more

10

Date

3/31/2020

11/14/2019

7/18/2018

2/2/2017

12/17/2015

Round

Series B

Corporate Minority - IV

Corporate Minority

Series A

Corporate Minority

Company

OrthoSpin

Founders Factory

S-Biomedic

Subscribe to see more

Subscribe to see more

Amount

$5M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

10

1

3

10

10

Johnson & Johnson Portfolio Exits

46 Portfolio Exits

Johnson & Johnson has 46 portfolio exits. Their latest portfolio exit was OrthoSpin on November 04, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/4/2021

Acquired

$991

8

11/1/2021

Divestiture

6

8/27/2019

Acquired - III

3

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

$991

Subscribe to see more

10

Date

11/4/2021

11/1/2021

8/27/2019

00/00/0000

00/00/0000

Exit

Acquired

Divestiture

Acquired - III

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

8

6

3

10

10

Johnson & Johnson Acquisitions

59 Acquisitions

Johnson & Johnson acquired 59 companies. Their latest acquisition was Momenta Pharmaceuticals on August 19, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/19/2020

IPO

$991

$45.68M

Acq - P2P

20

12/20/2019

Series B

$57M

Acquired

1

12/20/2019

Corporate Minority

Acquired

2

8/5/2019

Subscribe to see more

$991

$99M

Subscribe to see more

10

2/13/2019

Series E

Subscribe to see more

$991

$99M

Subscribe to see more

10

Date

8/19/2020

12/20/2019

12/20/2019

8/5/2019

2/13/2019

Investment Stage

IPO

Series B

Corporate Minority

Series E

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

$991

Total Funding

$45.68M

$57M

$99M

$99M

Note

Acq - P2P

Acquired

Acquired

Subscribe to see more

Subscribe to see more

Sources

20

1

2

10

10

Johnson & Johnson Partners & Customers

10 Partners and customers

Johnson & Johnson has 10 strategic partners and customers. Johnson & Johnson recently partnered with Mauna Kea Technologies on September 9, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

9/21/2021

Partner

Mauna Kea Technologies

France

J&J, Mauna Kea Technologies partner for Cellvizio platform study

Mauna Kea Technologies has signed a research collaboration agreement with Johnson & Johnson Medical Devices Companies 's Lung Cancer Initiative for the clinical study of the Cellvizio platform .

1

8/18/2021

Partner

Optellum

United Kingdom

Optellum Announces Strategic Collaboration With The Lung Cancer Initiative At Johnson & Johnson, Applying AI To Transform Early Lung Cancer Treatment

OXFORD , United Kingdom and HOUSTON , Aug. 18 , 2021 / PRNewswire / -- Optellum , a lung-health AI company , has entered a strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson * .

4

8/5/2021

Vendor

Lyfegen

Switzerland

1

7/29/2021

Vendor

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

7/15/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

9/21/2021

8/18/2021

8/5/2021

7/29/2021

7/15/2021

Type

Partner

Partner

Vendor

Vendor

Partner

Business Partner

Mauna Kea Technologies

Optellum

Lyfegen

Country

France

United Kingdom

Switzerland

Subscribe to see more

Subscribe to see more

News Snippet

J&J, Mauna Kea Technologies partner for Cellvizio platform study

Mauna Kea Technologies has signed a research collaboration agreement with Johnson & Johnson Medical Devices Companies 's Lung Cancer Initiative for the clinical study of the Cellvizio platform .

Optellum Announces Strategic Collaboration With The Lung Cancer Initiative At Johnson & Johnson, Applying AI To Transform Early Lung Cancer Treatment

OXFORD , United Kingdom and HOUSTON , Aug. 18 , 2021 / PRNewswire / -- Optellum , a lung-health AI company , has entered a strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson * .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

4

1

10

10

Johnson & Johnson Service Providers

1 Service Provider

Johnson & Johnson has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Acq - P2P

Investment Bank

Financial Advisor

Service Provider

Associated Rounds

Acq - P2P

Provider Type

Investment Bank

Service Type

Financial Advisor

Partnership data by VentureSource

Johnson & Johnson Team

111 Team Members

Johnson & Johnson has 111 team members, including current President, Vanessa Broadhurst.

Name

Work History

Title

Status

Vanessa Broadhurst

President

Current

Michael Chuisano

Chief Operating Officer

Current

Rowena Yeo

Chief Technology Officer

Current

Joyce Lee

Chief Information Officer

Current

Jijo James

Chief Medical Officer

Current

Name

Vanessa Broadhurst

Michael Chuisano

Rowena Yeo

Joyce Lee

Jijo James

Work History

Title

President

Chief Operating Officer

Chief Technology Officer

Chief Information Officer

Chief Medical Officer

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.